Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

The effect of a dentifric… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

The effect of a dentifrice in the prevention of recurrent aphthous stomatitis.

Artikel i vetenskaplig tidskrift
Författare Pierluigi Coli
Mats Jontell
Magnus Hakeberg
Publicerad i Oral health & preventive dentistry
Volym 2
Nummer/häfte 2
Sidor 133-41
ISSN 1602-1622
Publiceringsår 2004
Publicerad vid Odontologiska institutionen
Sidor 133-41
Språk en
Länkar www.ncbi.nlm.nih.gov/entrez/query.f...
Ämnesord Adolescent, Adult, Aged, Child, Dentifrices, analysis, therapeutic use, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Pain Measurement, Placebos, Stomatitis, Aphthous, pathology, physiopathology, prevention & control, Time Factors
Ämneskategorier Odontologi, Oral protetik

Sammanfattning

PURPOSE: A multicenter, double-blind, randomized, placebo-controlled clinical trial was conducted to determine the efficacy of an experimental dentifrice on the prevention of recurrent aphthous stomatitis (RAS). MATERIAL AND METHODS: A 3-month pretrial period was used to self-record data pertaining to the frequency, ulcer size, duration, and pain associated with ulcers. Thirty-six participants, who reported at least 3 RAS episodes or 30 days with RAS during the pretrial period, completed the study. Following a stratified randomization for age, sex and disease severity, the participants received the experimental dentifrice (T) or the placebo (C). The test period comprised 3 months of self-evaluation of number of ulcers, size and location. Pain related to RAS was estimated by the use of a Visual Analogue Scale (VAS). RESULTS: Symptoms were found to decrease in both groups when the pretrial and test periods were compared, although no statistical difference was reached in the C group. A statistically significant difference between the two time periods was obtained for the T group concerning the number of days with ulcers (p < 0.025) and VAS (p < 0.010). Of more clinical importance was the observation that 50% of the patients in the T group reported a more than 50% reduction in days with ulcers compared to 17% in the C group. CONCLUSIONS: The dentifrice may be used as a treatment strategy for a subgroup of patients with RAS in view of the low adverse effects and the benefit of using a treatment modality that is a part of daily routines.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?